Ladarixin, Placebo to match Ladarixin clinical trials

A phase 2, multicenter, randomized, double-blind, placebo-controlled study to assess the effect and safety of 400 mg twice a day oral ladarixin in patients with recent onset type 1 diabetes and a low residual β-cell function at baseline.

This study is testing a new medicine, ladarixin, for people recently diagnosed with Type 1 diabetes. Researchers want to see if it helps the body make more of its own insulin and if it's safe. Half will get the real medicine, half a dummy pill.